Global CBD Patch Market, By Product (Reservoir, Matrix, Layer Drug-In-Adhesive), Species (Cannabis Indica, Hybrid, Sativa), Packaging (Two to Five Patches, Single Patch, More Than Five Patch), Dosage (Below 30 mg, 30-40 mg, 40-50 mg, Above 50 mg), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC), Others), Application (Chronic Pain, Anxiety, Arthritis, Elevate Mood, Neurological Pain, Others), Source Type (Natural, Synthetic), End User (Homecare Setting, Research and Development Centers, Hospital, Clinics, Rehab Centers, Others), Distribution Channel (Dispensaries & Pharmacies, Online, Conventional Stores) - Industry Trends and Forecast To 2031.
CBD Patch Market Analysis and Size
CBD patches are convenient for users who may not want to consume CBD through traditional methods such as oils, capsules, or edibles. Patches provide a discreet and easy way to incorporate CBD into a daily routine. Transdermal patches deliver a slow and sustained release of CBD, providing longer-lasting effects compared to other consumption methods. This can be beneficial for individuals seeking a consistent and prolonged CBD experience. Unlike oral consumption, which involves the digestive system, transdermal patches bypass the digestive tract. This can be advantageous for people with sensitive stomachs or those who want to avoid the variability associated with oral ingestion.
Data Bridge Market Research analyzes that the CBD patch market, which was USD 324,986.93 Million in 2023, is likely to reach USD 624,171.30 Million by 2031 and is expected to undergo a CAGR of 8.5% during the forecast period. “Homecare Setting” dominates the end user segment of the CBD patch market due to the growing demand for CBD patches.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
CBD Patch Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product (Reservoir, Matrix, Layer Drug-In-Adhesive), Species (Cannabis Indica, Hybrid, Sativa), Packaging (Two to Five Patches, Single Patch, More Than Five Patch), Dosage (Below 30 mg, 30-40 mg, 40-50 mg, Above 50 mg), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC), Others), Application (Chronic Pain, Anxiety, Arthritis, Elevate Mood, Neurological Pain, Others), Source Type (Natural, Synthetic), End User (Homecare Setting, Research and Development Centers, Hospital, Clinics, Rehab Centers, Others), Distribution Channel (Dispensaries & Pharmacies, Online, Conventional Stores)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Sweden, Denmark, Poland, Rest of Europe, Japan, China, Australia, New Zealand, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Egypt, Ethiopia, Rest of the Middle East and Africa
|
|
Market Players Covered
|
Papa and Barkley (U.S.), Pure Ratios (U.S.), Charlotte’s Web (U.S.), Bioactive Solutions, Inc.(U.S.), La Mend Inc.(U.S.), Always Pure Organics Ltd (UK), Envy CBD (U.S.), GoGreen Hemp (U.S.), Harmony (Spain), Healist Naturals (U.S.), HempBombs.com (U.S.), Isodiol International Inc. (Canada), Kangdi Overseas Business Co., Ltd.(China), Manna Molecular (U.S.), Mary’s Medicinal (U.S.), Natures Script (U.S.), Nutrae, LLC.(U.S.), PureKana, SAVAN (U.S.), Shenzhen Ruiyan Technology Co., Ltd (China), Snowden Ltd.(U.S.), Social CBD (U.S.), Upstate Elevator Supply Co.(U.S.)
|
|
Market Opportunities
|
|
Market Definition
CBD patches offer a convenient and discreet method of CBD administration. Users can apply the patch to their skin, and it remains in place, allowing for continuous and controlled release of CBD without the need for repeated dosing or oral ingestion.
Global CBD Patch Market Dynamics
Drivers
- Rising Incidence of Chronic Diseases
The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders necessitates the development and administration of sterile injectable drugs. CBD patch play a crucial role in the treatment and management of chronic conditions. Pharmaceutical companies have an opportunity to focus on developing innovative injectable therapies for these diseases, addressing unmet medical needs.
- Advancements in Drug Delivery Technologies
Ongoing advancements in drug delivery technologies, such as prefilled syringes and autoinjectors, provide opportunities to enhance the administration and convenience of CBD patch. Companies can invest in research and development to improve drug delivery systems, making injections more patient-friendly and improving adherence to treatment regimens. Enhanced delivery technologies may also contribute to the development of self-administered injectables.
Opportunity
- Focus on Rare Diseases
The orphan drug market, including sterile injectables for rare diseases, represents an opportunity for companies to address unmet medical needs in niche patient populations. Companies can prioritize research and development efforts to create injectable therapies for rare diseases, benefiting from regulatory incentives and potentially establishing a strong market presence in specific therapeutic areas.
Restraint/Challenge
- High Development Cost
The research, development, and manufacturing of CBD patch involve significant costs, including expenses related to clinical trials, regulatory compliance, and adherence to stringent quality standards. The high upfront costs can be a barrier, particularly for smaller pharmaceutical companies. These financial challenges may limit the number of companies entering the market and potentially slow down the development of new injectable drugs.
Recent Development
- In May 2020, AbbVie Inc. acquired Allergan, a global company focused on manufacturing products targeting neuroscience, urology among other medical fields. This acquisition allowed the company to enhance its therapeutic categories and strengthen the company's financial values, which ultimately accelerated the company's research and developmental activities
Global CBD Patch Market Scope
The CBD patch market is segmented on the basis of product, application, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Reservoir
- Matrix
- Layer Drug-In-Adhesive
Species
- Cannabis Indica,
- Hybrid
- Sativa
Packaging
- Two to Five Patches
- Single Patch
- More Than Five Patch
Dosage
- Below 30 mg, 30-40 mg
- 40-50 mg
- Above 50 mg
Derivatives
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
- Others
Application
- Chronic Pain
- Anxiety
- Arthritis
- Elevate Mood
- Neurological Pain
- Others
Source Type
- Natural
- Synthetic
End User
- Homecare Settin
- Research and Development Centers
- Hospital
- Clinics
- Rehab Centers
- Others
Distribution Channel
- Dispensaries & Pharmacies
- Online
- Conventional Stores
Global CBD Patch Market Regional Analysis/Insights
The CBD patch market is analyzed and market size insights and trends are provided by country, product, application, end users, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Sweden, Denmark, Poland, rest of Europe, Japan, China, Australia, New Zealand, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Egypt, Ethiopia and rest of the Middle East and Africa.
North America is expected to dominate the market due to the presence of advanced healthcare infrastructure.
Asia-Pacific is the fastest-growing region in the market due to the rising prevalence of infectious diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The CBD patch market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the CBD patch market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the CBD patch market.
Competitive Landscape and CBD Patch Market Share Analysis
The CBD patch market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the CBD patch market.
Some of the major players operating in the CBD patch market are:
- Gilead Sciences, Inc. (U.S.)
- BIOCRYST PHARMACEUTICALS, INC.(U.S.)
- AstraZeneca (UK)
- Genentech, Inc. (a subsidiary of F. Hoffmann-La Roche Ltd.) (U.S.)
- Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) (U.S.)
- Hikma Pharmaceuticals PLC (UK)
- AbbVie Inc. (U.S.)
- American Regent, Inc. (a Daiichii Sankyo Group Company) (U.S.)
- Amgen Inc. (U.S.)
- Bristol- Myers Squibb Company (U.S.)
- Teligent (U.S.)
- Eisai Co., Ltd. (Japan)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Neuren Pharmaceuticals (Australia)
- Noxopharm (Australia)
- Amomed Pharma GmbH (Austria)
- Sanofi (France)
- Exelixis, Inc. (U.S.)
- Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA)(U.S.)
- Pfizer Inc. (U.S.)
SKU-